Want to see ESTA full AI Analyst Report?
ESTA Stock Chart & Stats
$67.08
-$0.07(-0.15%)
At close: 4:00 PM EST
$67.08
-$0.07(-0.15%)
Day’s Range― - ―
52-Week Range$33.35 - $90.50
Previous CloseN/A
Volume125.18K
Average Volume (3M)510.67K
Market Cap
$2.60B
Enterprise Value$2.62B
Total Cash (Recent Filing)$68.10M
Total Debt (Recent Filing)$263.96M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 11, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding29,430,390
10 Day Avg. Volume576,705
30 Day Avg. Volume510,665
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)91.68
Price to Sales (P/S)10.23
P/FCF Ratio-37.47
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue11.42
Enterprise Value/Gross Profit16.29
Enterprise Value/Ebitda-182.20
Forecast
1Y Price Target
$90.33Price Target Upside34.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.15
Revenue Forecast (FY)$267.19M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And U.S. ExpansionSustained double‑digit top‑line growth and explosive U.S. traction materially expand the company’s addressable market and diversify revenue mix. A growing U.S. share (>30% guided) supports higher-volume scale, improves pricing leverage and underpins durable revenue growth over the next several quarters.
High And Improving Gross Margins With Positive Adjusted EBITDASustained ~70% gross margins indicate structural product profitability and pricing power versus peers. Combined with consecutive positive adjusted EBITDA quarters, this margin profile supports a credible path to cash‑flow positivity and long‑term operating leverage as revenue scales, lessening sensitivity to cost fluctuations.
Product Differentiation And Strong Clinical Safety DataLow complication rates and early MIS adoption create a durable clinical and commercial moat, driving surgeon preference and willingness to pay premium prices. Strong safety/performance evidence accelerates surgeon certification and market share gains, supporting sustained pricing and reduced competitive pressure over months.
Bears Say
Persistent Negative Operating Cash FlowOngoing negative OCF and FCF mean the business still consumes material cash despite revenue gains. This creates reliance on external financing or rapid operational improvement to fund growth and working capital needs, leaving execution timelines (cash‑flow positive H2 2026) exposed to setbacks.
Reliance On Enlarged Debt Facility With PIK MechanicsPIK interest and added principal from optional accruals reduce near‑term cash interest but raise future debt burdens. Tighter covenants and lender oversight limit flexibility; if revenue or cash conversion slows, higher effective leverage could increase refinancing risk and constrain strategic choices.
Elevated Operating Expenses And SG&A Scaling RiskVery high SG&A as a percent of revenue means profitability depends heavily on rapid revenue scaling. Continued elevated spend to support U.S. launch increases execution risk: slower adoption or higher costs would delay margin conversion and pressure the pathway to sustained positive cash flow.
Establishment Labs Holdings News
ESTA FAQ
What was Establishment Labs Holdings Inc’s price range in the past 12 months?
Establishment Labs Holdings Inc lowest stock price was $33.35 and its highest was $90.50 in the past 12 months.
What is Establishment Labs Holdings Inc’s market cap?
Establishment Labs Holdings Inc’s market cap is $2.60B.
When is Establishment Labs Holdings Inc’s upcoming earnings report date?
Establishment Labs Holdings Inc’s upcoming earnings report date is Aug 11, 2026 which is in 42 days.
How were Establishment Labs Holdings Inc’s earnings last quarter?
Establishment Labs Holdings Inc released its earnings results on May 06, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.355 by -$0.095.
Is Establishment Labs Holdings Inc overvalued?
According to Wall Street analysts Establishment Labs Holdings Inc’s price is currently Undervalued.
Does Establishment Labs Holdings Inc pay dividends?
Establishment Labs Holdings Inc does not currently pay dividends.
What is Establishment Labs Holdings Inc’s EPS estimate?
Establishment Labs Holdings Inc’s EPS estimate is -0.34.
How many shares outstanding does Establishment Labs Holdings Inc have?
Establishment Labs Holdings Inc has 29,430,390 shares outstanding.
What happened to Establishment Labs Holdings Inc’s price movement after its last earnings report?
Establishment Labs Holdings Inc reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.355. Following the earnings report the stock price went up 5.001%.
Which hedge fund is a major shareholder of Establishment Labs Holdings Inc?
Currently, no hedge funds are holding shares in ESTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Establishment Labs Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.33 (34.67% Upside)
$90.33 (34.67% Upside)
Blogger Sentiment
Bullish
ESTA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.47%
12-Months-Change
Fundamentals
Return on Equity
-225.86%
Trailing 12-Months
Asset Growth
5.30%
Trailing 12-Months
Company Description
Establishment Labs Holdings Inc
Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.
ESTA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong operational and commercial momentum led by a rapid U.S. launch, 45% YoY revenue growth in Q1, improving gross margin (70.7%) and a return to positive adjusted EBITDA. Key product innovations (minimally invasive platform) are driving adoption, surgeon and patient demand, and management raised full-year revenue guidance. Offsetting factors include elevated operating expenses, near-term cash usage and increased debt with PIK mechanics, plus some supply and geopolitical uncertainties. Overall, the positives around revenue acceleration, margin expansion, product differentiation and pathway to cash-flow positivity materially outweigh the risks discussed.View all ESTA earnings summariesESTA Stock 12 Month Forecast
Average Price Target
$90.33
▲(34.67% Upside)
Technical Analysis
Ownership Overview
17.97% Insiders
6.02% Mutual Funds
63.12% Other Institutional Investors
11.50% Public Companies and
Individual Investors